ID

45407

Descrição

Principal Investigator: Mary V. Relling, Pharm.D., St. Jude Children Research Hospital, Pharmaceutical Sciences Department, Memphis, TN, USA MeSH: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000637 We estimated the plasma clearance of methotrexate from 1279 acute lymphoblastic leukemia (ALL) patients treated on the Children Oncology Group 9904 and 9905 trials (http://clinicaltrials.gov/show/NCT00005585 and http://clinicaltrials.gov/show/NCT00005596). Patients received either a 24-hour infusion of a 1 g/m2 dose or 4-hour infusion of a 2 g/m2 dose). Methotrexate clearance was lower in older children (p=7 x 10-7), females (p=2.7 x 10-4), and patients who received a delayed intensification phase (p=0.0022). In a genome-wide analysis, methotrexate clearance was associated with polymorphisms in the SLCO1B1 gene (p=2.1 x 10-11), which encodes for an organic anion transporter. This replicates findings using different schedules of high-dose methotrexate in ALL patients treated on St. Jude protocols. A combined meta-analysis yields a p-value of 5.7 x 10-19 for the association of methotrexate clearance with SLCO1B1 SNP rs4149056 (Trevino et al, PMID 19901119 and Ramsey et al, PMID 23233662). This data set includes the dependent variable of methotrexate clearance and all of the SNP data available from arrays.

Link

dbGaP study = phs000637

Palavras-chave

  1. 19/11/2022 19/11/2022 - Simon Heim
Titular dos direitos

Mary V. Relling, Pharm.D., St. Jude Children Research Hospital, Pharmaceutical Sciences Department, Memphis, TN, USA

Transferido a

19 de novembro de 2022

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

dbGaP phs000637 Methotrexate Clearance GWAS

Eligibility Criteria

Inclusion and exclusion criteria
Descrição

Inclusion and exclusion criteria

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0680251
Confirmed diagnosis of newly diagnosed B-precursor acute lymphocytic leukemia
Descrição

Confirmed diagnosis of newly diagnosed B-precursor acute lymphocytic leukemia

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C2585997
UMLS CUI [1,2]
C0750484
UMLS CUI [1,3]
C0349636
Participant is less than or equal to 21 years of age
Descrição

Participant is less than or equal to 21 years of age

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0001779
Written, informed consent following NCI, IRB, FDA, and OPRR Guidelines
Descrição

Written, informed consent following NCI, IRB, FDA, and OPRR Guidelines

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0021430
Patient received high-dose methotrexate as part of protocol-directed therapy for ALL
Descrição

Patient received high-dose methotrexate as part of protocol-directed therapy for ALL

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C5204889
UMLS CUI [1,2]
C0087111
UMLS CUI [1,3]
C0023449

Similar models

Eligibility Criteria

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
Inclusion and exclusion criteria
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
Confirmed diagnosis of newly diagnosed B-precursor acute lymphocytic leukemia
Item
Confirmed diagnosis of newly diagnosed B-precursor acute lymphocytic leukemia
boolean
C2585997 (UMLS CUI [1,1])
C0750484 (UMLS CUI [1,2])
C0349636 (UMLS CUI [1,3])
Participant is less than or equal to 21 years of age
Item
Participant is less than or equal to 21 years of age
boolean
C0001779 (UMLS CUI [1,1])
Written, informed consent following NCI, IRB, FDA, and OPRR Guidelines
Item
Written, informed consent following NCI, IRB, FDA, and OPRR Guidelines
boolean
C0021430 (UMLS CUI [1,1])
Patient received high-dose methotrexate as part of protocol-directed therapy for ALL
Item
Patient received high-dose methotrexate as part of protocol-directed therapy for ALL
boolean
C5204889 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C0023449 (UMLS CUI [1,3])

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial